Sawgrass Asset Management LLC Sells 2,005 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Sawgrass Asset Management LLC reduced its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,479 shares of the biotechnology company’s stock after selling 2,005 shares during the quarter. Sawgrass Asset Management LLC’s holdings in ADMA Biologics were worth $248,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. State Street Corp increased its holdings in ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC increased its holdings in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new stake in ADMA Biologics in the fourth quarter worth approximately $62,300,000. Assenagon Asset Management S.A. increased its holdings in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics in the third quarter valued at approximately $61,858,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ADMA has been the subject of a number of research reports. Raymond James raised their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Trading Up 1.5 %

Shares of ADMA Biologics stock opened at $16.08 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52 week low of $5.02 and a 52 week high of $23.64. The stock has a 50 day moving average price of $17.42 and a two-hundred day moving average price of $17.75. The stock has a market capitalization of $3.80 billion, a PE ratio of 57.43 and a beta of 0.75.

Insider Activity at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.70% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.